INCYIncyte Corporation

INCY Stock Price, Valuation & Chart | Incyte Corporation

Compare

$113.27+1.70 (+1.52%)

At close · 15 Oct 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology

Overview Financials Dividends Ratios

INCY Historical price chart

INCY Key Stats

Market Capitalization22.96B

PE Ratio15.22

EPS7.44

Trading Volume1.93M

Today's High/Low116.03/112.6

Dividend Yield0.00

52 Week High/Low132.6/84.02

Shares Outstanding202.70M

INCY Financial Statement

INCY Analyst ratings

INCY Analysis & performance metrics

INCY Company profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and…

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and…

INCY Management team

Name

Position

Christiana Stamoulis M.B.A.CFO

Executive Vice President & Chief Financial Officer

Ben Strain

Head of Investor Relations

Paula J. Swain

Executive Vice President of Human Resources

Michael James Morrissey

Executive Vice President & Head of Global Technical Operations

Thomas Tray

Vice President of Finance, Chief Accounting Officer & Controller

Sheila A. Denton J.D.

Executive Vice President, General Counsel & Corporate Secretary

Pablo J. Cagnoni M.D., Ph.D.

President and Head of Research & Development

Steven H. Stein M.D.

Executive Vice President & Chief Medical Officer

Name

Position

Christiana Stamoulis M.B.A.CFO

Executive Vice President & Chief Financial Officer

Ben Strain

Head of Investor Relations

Paula J. Swain

Executive Vice President of Human Resources

Michael James Morrissey

Executive Vice President & Head of Global Technical Operations

Thomas Tray

Vice President of Finance, Chief Accounting Officer & Controller

Sheila A. Denton J.D.

Executive Vice President, General Counsel & Corporate Secretary

Pablo J. Cagnoni M.D., Ph.D.

President and Head of Research & Development

Steven H. Stein M.D.

Executive Vice President & Chief Medical Officer

Management Team

Christiana Stamoulis M.B.A.CFO

Executive Vice President & Chief Financial Officer

Ben Strain

Head of Investor Relations

Paula J. Swain

Executive Vice President of Human Resources

Michael James Morrissey

Executive Vice President & Head of Global Technical Operations

Thomas Tray

Vice President of Finance, Chief Accounting Officer & Controller

Sheila A. Denton J.D.

Executive Vice President, General Counsel & Corporate Secretary

Pablo J. Cagnoni M.D., Ph.D.

President and Head of Research & Development

Steven H. Stein M.D.

Executive Vice President & Chief Medical Officer

Management

Christiana Stamoulis M.B.A.CFO

Executive Vice President & Chief Financial Officer

Ben Strain

Head of Investor Relations

Paula J. Swain

Executive Vice President of Human Resources

Michael James Morrissey

Executive Vice President & Head of Global Technical Operations

Thomas Tray

Vice President of Finance, Chief Accounting Officer & Controller

Sheila A. Denton J.D.

Executive Vice President, General Counsel & Corporate Secretary

Pablo J. Cagnoni M.D., Ph.D.

President and Head of Research & Development

Steven H. Stein M.D.

Executive Vice President & Chief Medical Officer

Total 8 executives

INCY Frequently asked questions

What is Incyte Corporation (INCY) Stock Price?

Current stock price of Incyte Corporation (INCY) stock is $113.27. The stock price is +1.52% higher in the session. The intraday range can be seen from this page. Volume of Incyte Corporation (INCY) stock is 1.93M.

Last updated at 15 Oct 2026, 08:00 pm.

Why is the Incyte Corporation (INCY) stock price going up or down today?

The stock price of Incyte Corporation (INCY) can change with earnings, company news, and overall market sentiment. Incyte Corporation operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Incyte Corporation stock expensive at its current price?

Whether Incyte Corporation looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for INCY on this page is 15.22. EPS on this page is 7.44. Compare those figures with peers and growth expectations before deciding if the current Incyte Corporation price is justified.

How has the stock price of Incyte Corporation (INCY) performed historically?

Historical performance for Incyte Corporation (INCY) is shown on the price chart on this page. Review multi-period moves alongside volume to see how INCY reacted to past earnings and market events.

Should I buy Incyte Corporation (INCY) stock, at this price?

Buying Incyte Corporation (INCY) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.